Efficacy Study of Cilostazol and Aspirin on Cerebral Small Vessel Disease
NCT01932203, Phase 4, Unknown, Inha University Hospital
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Efficacy Study of Cilostazol and Aspirin on Cerebral Small Vessel Disease | ClinicalTrials.gov |
| NCT number | NCT01932203 | ClinicalTrials.gov |
| Status | Unknown | ClinicalTrials.gov |
| Phases | Phase 4 | ClinicalTrials.gov |
| Enrollment | 255 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Inha University Hospital | ClinicalTrials.gov |
| Conditions | Cerebral Small Vessel Disease | ClinicalTrials.gov |
| Interventions | aspirin, cilostazol | ClinicalTrials.gov |
| First posted | 2013-08-30 | ClinicalTrials.gov |
| Last updated | 2019-08-08 | ClinicalTrials.gov |
Registered outcomes 18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Volume of white matter changes (WMCs) | baseline, week 104 | Measure change of WMC on brain MRI | ClinicalTrials.gov |
| Secondary | Mean diffusivity (MD) and Fraction Anisotropy (FA) on Diffusion Tensor Imaging | baseline and week 104 | High MD and low FA means tissue damage. | ClinicalTrials.gov |
| Secondary | Number of lacunes | baseline and week 104 | High number means tissue damage. | ClinicalTrials.gov |
| Secondary | number of microbleeds | baseline and week 104 | High number means tissue damage. | ClinicalTrials.gov |
| Secondary | brain volume and cortical thickness | baseline and week 104 | Low score means tissue damage. | ClinicalTrials.gov |
| Secondary | Mini-Mental State Examination | baseline, week 52, and week 104 | Measure global cognition. Score range is 0-30. Higher score means good cognition. | ClinicalTrials.gov |
| Secondary | Neurocognitive test | baseline, week 52, and week 104 | Seoul Verbal Learning Test, Boston Naming test-short form, ROCF copy, animal fluency, phonemic fluency, Stroop test, Digit-symbol test, Trail making test | ClinicalTrials.gov |
| Secondary | Clinical Dementia Rating scale-sum of boxes | baseline, week 52, and week 104 | Measure global cognition. Score range is 0-18. Higher score means good cognition. | ClinicalTrials.gov |
| Secondary | King's Health Questionnaire | baseline, week 42, and week 104 | Measure voiding function. Higher score means bad function. | ClinicalTrials.gov |
| Secondary | Geriatric Depression Scale-Short form | baseline, week 52, and week 104 | Measure depression. Score range is 0-15. Higher score means depression. | ClinicalTrials.gov |
| Secondary | Caregiver-Administered Neuropsychiatric Inventory (CGA-NPI) | baseline, week 52, and week 104 | Measure abnormal behavior. Score range is 0-144. Higher score means severe abnormal behavior. | ClinicalTrials.gov |
| Secondary | Bayer Activities of Daily Living | baseline, week 52, and week 104 | Measure instrumental activities of daily living (ADL). Score range is 1-10. Higher score means bad ADL. | ClinicalTrials.gov |
| Secondary | Barthel Index | baseline, week 52, and week 104 | Measure physical ADL. Score range is 0-20. Higher score means good physical ADL. | ClinicalTrials.gov |
| Secondary | Pyramidal and Extrapyramidal Scale (PEPS) | baseline, week 52, and week 104 | Measure neurologic signs. Score range is 0-60. Higher score means many abnormal neurologic signs. | ClinicalTrials.gov |
| Secondary | Timed UP and Go (TUG) test | basline, week 52, and week 104 | Measure gait. Higher score means bad gait. | ClinicalTrials.gov |
| Secondary | Adverse event | baseline, week 4, 16, 28, 40, 52, 64, 76, 88, and 104 | measure any adverse events | ClinicalTrials.gov |
| Other | All ischemic stroke event | week 104 | cerebral infarction and transient ischemic attack | ClinicalTrials.gov |
| Other | All vascular events | week 104 | including ischemic stroke, transient ischemic attack, myocardial infarction, angina pectoris, cerebral venous thrombosis, pulmonary embolism, symptomatic deep vein thrombosis, symptomatic peripheral artery occlusion, other vascular occlusion, and any revascularization procedure | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 3
The papers the trial lists on ClinicalTrials.gov.
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 8
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Category Fluency | Secondary outcome | ConductCognition |
| Picture Naming Test | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Symbol Coding | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
| Verbal Fluency | Secondary outcome | ConductCognition |
| Verbal Learning | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)